Search Results

Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.

Allogene Therapeutics, Inc. and Arbor Biotechnologies, Inc. today announced a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease (AID).

Daicel Arbor Biosciences is excited to announce the release of the next generation of its myTXTL® kits, for cell-free protein expression, designed to simplify and accelerate antibody discovery and protein engineering.

The life science group Sartorius opened its new Center of Excellence for bioanalytics in Ann Arbor, Michigan, two years after breaking ground in the Tech Loop at Research Park.

Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced four upcoming presentations at the 2024 American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place May 7-11 in Baltimore, Maryland.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) and Arbor Biotechnologies, Inc. (Arbor) today announced a strategic partnership focused on advancing new AAV-based gene-editing therapies for central nervous system (CNS) diseases with high unmet medical needs in both rare and common disease populations.

Arbor Biotechnologies® presents preclinical data demonstrating the potential of ABO-101, its novel gene editing therapeutic designed to address primary hyperoxaluria type 1, as well as its broader discovery capabilities and their application to enable novel gene editing therapeutics in a suite of presentations at the 2024 American Society of Gene and Cell Therapy 27th Annual Meeting in Baltimore, Maryland.

Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of R. Nolan Townsend to the Company’s Board of Directors.

Blue Arbor Technologies Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the RESTORE™ Neuromuscular Interface System for people with upper limb loss.